Home > Keywords > Thématique > Science

Science

Articles

  • New PCT patent application covering anti Transferrin receptor vectors
    13 October 2020, by Elodie DORMES

    Vect-Horus has filed a PCT patent application covering a library of vectors that target the Transferrin receptor (TfR). This patent strengthens the intellectual property of the Company with a portfolio containing now 6 patent families. This confirms its position as a major player in Blood-Brain Barrier drug delivery technology.

  • Society for the study of Blood-Brain interfaces SEISC 2019 congres
    27 November 2019, by Elodie DORMES

    Stéphane GIRARD will present iPS cell-derived model of the human blood-brain-barrier on Friday 15, Nov Session 1 of the Society for the study of Blood-Brain interfaces SEISC 2019 congres in Paris

  • Vect-Horus strengthens its scientific advisory board with the appointment of Dr. Julia ALTERMAN
    22 March 2022, by Elodie DORMES

    Vect-Horus extends its Scientific Advisory Board with the expertise of Dr. Julia Alterman on siRNA chemical modification for extra-hepatic delivery.

  • Vect-Horus will join the ARVO Annual Meeting
    17 April 2024, by Emmanuelle BETTENDORF

    We’re excited to present a poster on our targeted drug delivery technology at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting, taking place in Seattle, WA, USA from May 5-9, 2024.
    The poster is titled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”.
    It will be available at ARVO on May 7, 2024, from 3:30pm to 5:15pm PDT Posterboard Number 3992 - B0036 and Session (…)

  • Early September VECT-HORUS’ team will be attending the EANM2023 Annual Congress!
    8 September 2023, by Emmanuelle BETTENDORF

    On this occasion, our partner Radiomedix, Inc. , was selected to present an update of our joint research program. This talk untitled “Glioblastoma and Pancreatic Adenocarcinoma - Versatile radiolabeled probe targeting Low Density Lipoprotein Receptors (LDLR)” will be given Sunday, September 10th between 4:55 PM and 5:05 PM at the Hall E2 by Izabela Tworowska.
    Come and take the opportunity to meet and discuss with Vect-Horus on September 9-13, 2023 in Vienna!
    Our #Oncology team, Cedric (…)

  • Festival of Biologics 2019 in BASEL
    31 October 2019, by Elodie DORMES

    Meet with Pascaline LECORCHE during the Festival of Biologics 2019, 15 – 17 October 2019 _ Basel Switzerland and discuss on « Design of peptide-based vectors for targeted delivery ».

  • Vect-Horus will join the Single-Domain Antibodies Summit
    14 September 2023, by Emmanuelle BETTENDORF

    Vect-Horus Vector Discovery Team will attend the Single Domain Antibodies Summit that will be held in Paris from 18th to 20th of September 2023.
    Interesting sessions are planned and Vect-Horus will attend the one dedicated to “Single domain Antibodies engineering and structure” and of course “Single domain Antibodies in neurobiology”.
    We look forward to discussing with the scientific community attending this meeting and sharing with them our last advances in the use of nanobodies as (…)

  • Meet Vect-Horus at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit, Boston, August 21-23, 2024
    21 August 2024, by Emmanuelle BETTENDORF

    VECT-HORUS S.A.S. will be presenting a poster at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit!
    This high-profile event is taking place in Boston, MA from August 20-22, and Pavlo Shpak-Kraievskyi, Project leader, is looking forward to attending.
    Poster Title: VECTrans® Technology for CNS Targeting by Lipid Nanoparticles
    📆 Save the date: 3:30pm ET, Wednesday August 21st
    🌐 Learn More: https://ter.li/b5vw3f

  • AD/PD 2019​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in LISBON
    28 January 2019, by Jonathan NOWAK

    Marion DAVID and Romy COHEN will present the “Development of vectors that cross the blood brain barrier to enhance CNS drug delivery in neurodegenerative diseases” in session A: β-Amyloid Diseases poster n°ADPD9-1832

  • Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member
    14 November 2024, by Emmanuelle BETTENDORF

    We’re pleased to welcome Jean-Christophe Dantonel as a new member of the Vect-Horus Board of Directors!
    Dr. Dantonel brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.
    “He brings key skills to our company at an important stage of its development, with a combination of clinical research and business experience which will be invaluable as we innovate to develop vectors that facilitate targeting and delivery of (…)